Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Dowlati A, et al. Among authors: izumi h. J Clin Oncol. 2024 Oct 10;42(29):3392-3399. doi: 10.1200/JCO.24.00553. Epub 2024 Aug 29. J Clin Oncol. 2024. PMID: 39208379 Free PMC article. Clinical Trial.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: izumi h. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Umemura S, et al. Among authors: izumi h. J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378-5. doi: 10.1016/j.jtho.2024.10.004. Online ahead of print. J Thorac Oncol. 2024. PMID: 39395663
Development of fever following first administration of zoledronate as a prognostic factor in advanced non-small cell lung cancer patients with bone metastases.
Izumi H, Igishi T, Yamasaki A, Takeda K, Yanai M, Tanaka N, Sakamoto T, Nishii-Ito S, Touge H, Kodani M, Matsumoto S, Kawasaki Y, Shimizu E. Izumi H, et al. Mol Clin Oncol. 2017 Dec;7(6):1000-1004. doi: 10.3892/mco.2017.1447. Epub 2017 Oct 10. Mol Clin Oncol. 2017. PMID: 29285363 Free PMC article.
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K. Sugimoto A, et al. Among authors: izumi h. Clin Cancer Res. 2023 Apr 14;29(8):1506-1514. doi: 10.1158/1078-0432.CCR-22-1749. Clin Cancer Res. 2023. PMID: 36201167
A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E. Sakamoto T, et al. Among authors: izumi h. Int J Oncol. 2015 Apr;46(4):1473-80. doi: 10.3892/ijo.2015.2875. Epub 2015 Feb 4. Int J Oncol. 2015. PMID: 25651992 Free PMC article.
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M, Murakami S, Kawakami H, Okishio K, Tamiya M, Kobayashi H, Fujimoto D, Sugawara S, Kozuki T, Oya Y, Izumi H, Shiroyama T, Satouchi M, Yamamoto N, Kaname S, Matsuoka D, Otake Y, Takase T, Semba T, Azuma K. Nishio M, et al. Among authors: izumi h. Cancer Res Commun. 2024 Jan 29;4(1):226-235. doi: 10.1158/2767-9764.CRC-23-0313. Cancer Res Commun. 2024. PMID: 38181055 Free PMC article. Clinical Trial.
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.
Niho S, Goto Y, Toyozawa R, Daga H, Ohashi K, Takahashi T, Tanaka H, Sakakibara-Konishi J, Hattori Y, Morise M, Kodani M, Ikeda T, Izumi H, Matsumoto S, Yoh K, Nomura S, Goto K. Niho S, et al. Among authors: izumi h. ESMO Open. 2024 Aug;9(8):103642. doi: 10.1016/j.esmoop.2024.103642. Epub 2024 Jul 16. ESMO Open. 2024. PMID: 39018589 Free PMC article. Clinical Trial.
1,047 results